Evidence map›Paper›PMID 38026393›Full record

ArticleFrontiers in public health2023

Characterizing the role of human behavior in the effectiveness of contact-tracing applications.

Ariadna Fosch, Alberto Aleta, Yamir Moreno

Abstract read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ariadna FoschInstitute for Biocomputation and Physics of Complex Systems, University of Zaragoza, Zaragoza, Spain.
Alberto AletaInstitute for Biocomputation and Physics of Complex Systems, University of Zaragoza, Zaragoza, Spain.
Yamir MorenoInstitute for Biocomputation and Physics of Complex Systems, University of Zaragoza, Zaragoza, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Although numerous countries relied on contact-tracing (CT) applications as an epidemic control measure against the COVID-19 pandemic, the debate around their effectiveness is still open. Most studies indicate that very high levels of adoption are required to stop disease progression, placing the main interest of policymakers in promoting app adherence. However, other factors of human behavior, like delays in adherence or heterogeneous compliance, are often disregarded. Methods: To characterize the impact of human behavior on the effectiveness of CT apps we propose a multilayer network model reflecting the co-evolution of an epidemic outbreak and the app adoption dynamics over a synthetic population generated from survey data. The model was initialized to produce epidemic outbreaks resembling the first wave of the COVID-19 pandemic and was used to explore the impact of different changes in behavioral features in peak incidence and maximal prevalence. Results: The results corroborate the relevance of the number of users for the effectiveness of CT apps but also highlight the need for early adoption and, at least, moderate levels of compliance, which are factors often not considered by most policymakers. Discussion: The insight obtained was used to identify a bottleneck in the implementation of several apps, such as the Spanish CT app, where we hypothesize that a simplification of the reporting system could result in increased effectiveness through a rise in the levels of compliance.

Indexed as

COVID-19Mobile ApplicationsContact TracingCOVID-19 TestingHumansPandemicscomputational modelingcontact-tracing appsCOVID-19digital contact-tracingepidemic modelinghuman behaviormultilayer networks

Identifiers

PMID38026393
PMCPMC10657191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.